Guide RNA and genetic modification method in escherichia coli host microorganism for target gene expression using the crispr / CAS system
The CRISPR/Cas system with a gRNA plasmid and REDCas-Cm plasmid facilitates precise genetic modification in E. coli strains, achieving high efficiency and minimal metabolic disruption for targeted gene expression.
Patent Information
- Application Number
- PCT/IB2026/054282
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-04-30
- Publication Date
- 2026-11-12
AI Technical Summary
Current genetic modification methods in Escherichia coli (E. coli) strains such as E. coli C, E. coli MYR428, and E. coli MYR1674 are inefficient and imprecise, often resulting in incorrect gene insertions, low expression efficiency, and disruption of metabolic pathways or cell growth, particularly under stress conditions.
A method using the CRISPR/Cas system for genetic modification, involving a gRNA plasmid specific to a designated intergenic region, a REDCas-Cm plasmid for DNA recombination, and a repair template, followed by removal of the plasmids to achieve precise gene insertion or substitution in E. coli strains.
The method enables precise genetic modification with high efficiency, ensuring effective gene expression and minimal disruption to metabolic pathways, as demonstrated by consistent gene insertion and expression in E. coli strains.
Smart Images

Figure IB2026054282_12112026_PF_FP_ABST
Abstract
Description
[0001] TITLE OF THE INVENTION
[0002] GUIDE RNA AND GENETIC MODIFICATION METHOD IN ESCHERICHIA COLI HOST MICROORGANISM FOR TARGET GENE EXPRESSION USING THE CRISPR / CAS SYSTEM
[0003] TECHNICAL FIELD
[0004] The present invention relates to the field of biochemistry and biotechnology, in particular, to the process of identifying locations on the genome of microorganisms and genetic modification using the CRISPR / Cas system.
[0005] BACKGROUND ART
[0006] Currently, synthetic biology technology is widely used to design metabolic pathway in microorganisms in several purposes such as the modification of the microorganisms to have new activities or capabilities, the modification of the microorganisms for the synthesis of biochemicals, or for the applications in agricultural and medical industries. The modification of the microorganisms requires alterations at the gene or nucleic acid level. To be specific to the target gene or nucleic acid, in addition to the system used for modification, the specific region or location to be modified must be the region that will not affect the metabolic pathway or affect the growth of the microorganism cells.
[0007] An example of genome modification in yeast for producing lactic acid by synthetic biology method is disclosed in Ishida N. et al., 2005. This work discloses the increasing of lactic acid product by converting pyruvic acid to lactic acid by removing pyruvate dehydrogenase gene that normally related to the process that converting pyruvic acid to acetyl-CoA and replacing it with lactate dehydrogenase gene to produce more lactic acid from pyruvic acid. However, the critical pyruvate dehydrogenase genes in yeast are pyruvate dehydrogenase- 1 and pyruvate dehydrogenase-5 genes. When both genes are removed, yeast cell cannot grow normally in the medium because these genes are crucial to the metabolic pathway. Therefore, the insertion of desired genes in the region that will not affect the metabolic pathway, or the growth of microorganism cells is very necessary.
[0008] An example of gene insertion at various locations on the genome using the red fluorescent protein gene as a marker, as shown in Sauer C. et al., 2016, reports four different locations on the E. coli genome that resulted in varying expressions of the red fluorescentprotein. The red fluorescent caused by protein expression has different intensity, and at some genomic locations, incorrect gene insertions occurred, yielding gene sizes that were not as desired or having a correct insertion efficiency of less than 50%. Therefore, apart from finding genomic locations for genetic modification that do not disrupt metabolic pathways or cell growth, the desired gene expression must also be considered.In order to solve these problems, an effort was made to invent a process for finding locations on the microbial genome using accurate and precise genetic modification processes. Currently, several methods can genetically modify microorganisms. Currently, there are several processes that can genetically modify microorganisms. An example of genetic modification using a suicide plasmid in bacteria, as shown in Wang T. et al., 2019, utilizes a double crossover technique by inserting the desired gene along with this suicide plasmid. After the cells are modified, , they are selected using a selection marker gene, such as the levansucrase gene, that capable for converting sucrose into levan which is toxic to bacterium cells. Therefore, after the bacterium cells have been modified, adding of sucrose allows only the bacterial cells without the suicide plasmid to grow. This is the natural selection for selecting modified bacteria whose plasmid has been removed. However, this technique has efficiency limitations because the use of double crossover technique results in 50 % of wild-type bacteria or half of the total bacteria. Theoretically, genetic modification occurs only in the remaining 50%, and research reports that the actual experimental efficiency is often much lower than 50%.
[0009] Moreover, the microorganism used in the modification plays a vital role in the genome modification of Escherichia coli or E. coli which is a widely used bacterium in science laboratories because it is the microorganism with rapid growth. Nevertheless, there are many strains of E. coli, but five are commonly used in labs: Strain C, Strain K12, Strain B, Strain W, and Strain Crooks. Previous research shows Strain KI 2 can be used for genetic modification, but it has a low tolerance to environmental stresses, such as high salt concentrations (Krol J.E. et al., 2019) or other stress conditions. Therefore, according to the present invention, the suitable host microorganism is E. coli. In the embodiment of this invention, the most suitable host microorganism are selected from E. coli C, E. coli MYR428, E. coli MYR1674, modified E. coli C (E. coli C derivatives), modified E. coli MYR428 (E. coli MYR428 derivatives), and modified E. coli MYR1674 (E. coli MYR1674 derivatives). E. coli MYR428 is a modified strain derived from E. coli C host microorganism. E. coli MYR1674 is a modified strain derived from E. coliMYR428 host microorganism. Both strains are highly tolerant and can produce biofilm when facing stress conditions, which helps the microorganism cells to grow. Currently, there is no disclosure of guide RNA (gRNA) that is suitable for the genetic modification of these specific microorganisms.
[0010] From said problems and disadvantages, an attempt has been made to develop a process for finding locations on the genome of E. coli C, E. coli MYR428, and E. coli MYR1674, including their derived strains, to enable the synthesis of diverse products and to apply an efficient and precise genetic modification method using the CRISPR / Cas system which is the effective system in genetic modification. Identifying locations on the microbial genome will benefit future research, as it allows for genetic modification at positions that yield excellent gene expression and facilitates microbial modification for the synthesis of useful industrial products.
[0011] SUMMARY OF INVENTION
[0012] The present invention relates to the genetic modification method of the host microorganism E. coli for target gene expression using the CRISPR / Cas system. The method comprises transferring the target gene into a designated intergenic region of the host microorganism using the CRISPR / Cas system. The CRISPR / Cas system comprising: (i) a gRNA plasmid comprising the gRNA specific to the designated intergenic region; (ii) a REDCas-Cm plasmid; and (iii) a repair template comprising a nucleotide sequence of the target gene; and removing the gRNA plasmid and the REDCas-Cm plasmid from the genetic modified microorganism.
[0013] The CRISPR / Cas system for use in the genetic modification of microorganism comprising: 1) a gRNA plasmid wherein this plasmid comprising a guide RNA (gRNA) that specific to the target region; 2) a REDCas-Cm plasmid wherein this plasmid comprising a gene causing the expression of the Cas endonuclease enzyme specific to the gRNA sequence, the REDCas-Cm plasmid also comprising genes causing the expression of the Lambda-red comprising gam, beta, and exo proteins that facilitate in the DNA recombination process; and 3) a repair template which is the nucleotide sequence of the gene to be inserted or the gene on genome to be removed, or for the substitution of gene on desired genome to be removed by the inserted gene as shown in figure 1.The genetic modification process employing CRISPR / Cas system needs the CRISPR / Cas system for the modification of the microorganism comprising: 1) a gRNA plasmid wherein this plasmid comprising a guide RNA (gRNA) specific to the target region; 2) a REDCas-Cm plasmid wherein this plasmid comprising a gene causing the expression of the Cas endonuclease enzyme specific to the gRNA sequence, It also contains genes causing the expression of the Lambda-red system comprising gam, beta, and exo proteins that facilitate the DNA recombination process; and 3) a repair template which is the nucleotide sequence of gene to be inserted or gene on genome to be removed, and need to have the microorganism to be modified such as E. coli C, E. coli MYR428, and E. coli MYR1674.
[0014] BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 shows the structure of the CRISPR / Cas system and the assembling of genetic components to construct the gRNA plasmid and the REDCas-Cm plasmid.
[0016] Figure 2 shows one aspect of the genetic modification method using target gene insertion.
[0017] Figure 3 shows one aspect of the genetic modification method using target gene substitution.
[0018] Figure 4 is the graph presenting fluorescence intensity resulting from rfp gene expression which leads to producing RFP protein when the target gene is inserted at various specific intergenic regions of modified E. coli MYR1674.
[0019] Figure 5 is the graph presenting luminescence intensity from modified E. coli MYR428 and E. coli MYR1674 having the T7 map gene inserted into the genome and possessing a plasmid vector with the luxCDEAB gene under the T7 promoter, leading to the expression of luciferase.
[0020] DESCRIPTION OF THE INVENTION
[0021] In the following description:
[0022] According to this patent application, phase “for example” or “such as” aims to show that there are more than one method, way, solution, or composition of the substance for this subject, and the provided example does not aim to limit such example.
[0023] Technical terms or scientific terms used here have definitions as by person skilled in the art unless stated otherwise. In order to help the understanding in the invention, the explanation of name system is provided below.Devices, equipment, methods, materials, or chemicals named here mean devices, equipment, methods, materials, or chemicals being used commonly by person skilled in the art unless clearly stated otherwise that they are tools, equipment, methods, materials, or chemicals specifically used in this invention.
[0024] Use of singular noun or singular pronoun with “comprising” in claims or specification means “one” and including “one or more”, “at least one”, and “one or more than one” too.
[0025] All compositions and / or methods disclosed and claims in this application aim to cover embodiments from any action, performance, modification, or adjustment without any experiment that is significantly different from this invention and obtain with object with utility and resulted as same as the present embodiment according to person ordinary skilled in the art although without specifically stated in claims. Therefore, substitutable or similar object to the present embodiment, including any little modification or adjustment that clearly seen by person skilled in the art should be construed as remains in spirit, scope, and concept of invention as appeared in appended claims.
[0026] Throughout this application, term “about” means any number that appeared or showed here that could be varied or deviated from any error of equipment, method, or personal using said equipment or method including the variation or deviation caused by the change of the physical properties.
[0027] In order to help the understanding in the invention, terms are defined below and other terms can be found in the specification.
[0028] “Target gene” means any one or more genes desired for expression or use according to the objective. Preferable (but not limitation), it may include genes expressing proteins and / or enzymes for synthesizing products, transcription genes (e.g., T7 map), and fluorescent protein genes (e.g., rfp, gfp, yfp). “Intergenic regions” comprise nucleotide sequences which are parts of the genome located between two genes, wherein said intergenic regions are non-coding regions but may have other function such as the regulatory elements.
[0029] “Original” means polypeptide or polynucleotide that has no genetic modification.
[0030] “Stem cells” means original cells or cells having no genetic modification.
[0031] “Genetic engineering” or “genetically engineered” means the activity of inputting one or more genetic modification into cells or cells produced by this activity.“Genetic modification” means artificial change in specific aspects or structures of the genetic materials of the cells. Genetic modification includes the inputting of polynucleotide that encoding polypeptide into cells of substitution, insertion, addition, deletion, detection, interference, and repress of one or more nucleotide that is related in the genetic materials of the stem cells or the chemical modification of the genetic materials of the stem cells.
[0032] “ coli C” means E. coli strain C (ATCC 8739).
[0033] “E. coli MYR428” means E. coli strain MYR428 (details according to US patent application no. 17 / 326,643).
[0034] “E. coli MYR1674” means E. coli strain MYR1674 (details according to US patent application no. 17 / 326,643).
[0035] “E. coli C derivatives” means E. coli strain C that have been genetically engineered or genetically modified. Their nucleotide sequences in genome are different from the original E. coli C. It can be the insertion of DNA into E. coli C or the deletion of DNA in E. coli C, or any other method that alters the sequence of nucleotide in the genome of E. coli C. They are all called E. coli C derivatives.
[0036] “E. coli MYR428 derivatives” means E. coli strain MYR428 that have been genetically engineered or genetically modified. Their nucleotide sequences in genome are different from the original E. coli MYR428. It can be the insertion of DNA into E. coli MYR428 or the deletion of DNA in E. coli MYR428, or any other method that alters the sequence of nucleotide in the genome of E. coli MYR428. They are all called E. coli MYR428 derivatives.
[0037] “E. coli MYR1674 derivatives” means E. coli strain MYR1674 that have been genetically engineered or genetically modified. Their nucleotide sequences in genome are different from the original E. coli MYR1674. It can be the insertion of DNA into E. coli MYR1674 or the deletion of DNA in E. coli MYR1674, or any other method that alters the sequence of nucleotide in the genome of E. coli MYR1674. They are all called E. coli MYR1674 derivatives.
[0038] “CRISPR / Cas (clustered regularly interspaced short palindromic repeat / CRISPR-associated proteins) system” means a specific immune system of bacteria adapted for using as a genetic tool in organisms. CRISPR has a guide RNA (gRNA) as its component functions as genetic code marker and guide for protein or enzyme Cas. The protein or enzyme Cas is enzyme functions in recognition and specifically cut at the CRISPR region. The CRISPR / Cas system isobtained for performing genetic engineering using the repair template for completing the genetic modification in organisms.
[0039] “Plasmid vector” or “vector DNA” is circular DNA used to amplify a large quantity of a desired DNA fragment by assembling the DNA fragment into a plasmid vector to form Recombinant DNA, or it can be used to assemble other components such as guide RNA or other parts.
[0040] “Guide RNA” or “gRNA” means a short nucleotide fragment of 17 to 20 bases having a sequence identical to the genetic material of the host microorganism, acting as a guide to be recognized by the Cas enzyme.
[0041] “Cas” is a protein or endonuclease enzyme capable of specifically cutting the genetic material of the host microorganism by recognizing the specific cleavage site according to the nucleotide sequence of the guide RNA. There are various types of Cas enzymes, including Cas9, Cas 12, Cas 13, and other endonuclease enzymes such as Cpf.
[0042] “Repair template” is linear DNA used for repairing the genomic DNA at the part specifically cut by the endonuclease enzyme.lt can be designed to be suitable for repairing by using the nucleotides of the gene to be inserted or gene on genome to be removed, or insertion of gene on genome to be removed by the gene to be inserted, etc.
[0043] The use of “gene”, “protein”, and “enzyme” such as the cas9 gene refers to the gene capable of producing the Cas9 enzyme. The rfp gene refers to the gene capable of producing the RFP (Red Fluorescent Protein). The T7 map gene refers to the gene capable of producing the T7 RNA polymerase enzyme. In some aspects, the consideration of being gene or protein or enzyme product depends on the specific context.
[0044] This disclosure relates to the process of identifying locations on the microbial genome and genetic modification using CRISPR / Cas system using genetic engineering technique related to nucleotides, DNA, RNA, genes, proteins, and enzymes related to the genetic modification and the verification of gene expression.
[0045] Hereinafter, various embodiments of the invention are presented without any intention to limit the scope of the invention.
[0046] Genetic modification method of Escherichia coli host microorganism for target gene the CRISPR / CasThis invention relates to a method for the genetic modification of the host microorganism Escherichia coli for target gene expression using the CRISPR / Cas system comprises the following steps:
[0047] a. introducing the target gene into a designated intergenic region of the host microorganism using the CRISPR / Cas system;
[0048] wherein the CRISPR / Cas system comprising: (i) a gRNA plasmid comprising a guide RNA (gRNA) specific to specific to the target modification site on the intergenic region; (ii) a REDCas-Cm plasmid; and (iii) a repair template comprising the nucleotide sequence of the target gene; and
[0049] b. removing the gRNA plasmid and the REDCas-Cm plasmid from the genetically modified microorganism.
[0050] Preferably, the genetic modification of the host microorganism for target gene expression according to this invention, a suitable host microorganism is Escherichia coli.
[0051] Most preferably, the genetic modification of the host microorganism for target gene expression according to this invention, the most suitable Escherichia coli host microorganism is selected from Escherichia coli C, Escherichia coli MYR428, Escherichia coli MYR1674, modified Escherichia coli C (Escherichia coli C derivatives), modified Escherichia coli MYR428 (Escherichia coli MYR428 derivatives), and modified Escherichia coli MYR1674 (Escherichia coli MYR1674 derivatives).
[0052] The method for identifying a specific intergenic region of the host microorganism for target gene introduction may start by searching all nucleotide sequences in the genome of the microorganism, which is E. coli. Subsequently, all genes in the microorganism's genome are identified to locate intergenic regions. The selected intergenic gaps have a length of at least 500 base pairs to avoid interfering with the function or expression of other nearby genes that might be protein-expressing genes, or regions controlling gene expression such as promoters or terminators. After identifying the locations of the intergenic regions, the nucleotide sequences of these various intergenic locations are searched against databases to avoid them being essential elements affecting the expression of other adjacent genes.
[0053] Then, specific nucleotide sequences of guide RNA (gRNA) are designed corresponding to the nucleotide sequences of the host microorganism's intergenic regions (as shown in Table 1) to be used in constructing the gRNA plasmid vector.Table 1: The nucleotide sequences of the guide RNA (gRNA) specific to the nucleotide sequences of the host microorganism
[0054] Intergenic region gRNA SEQ ID NO Nucleotide sequence (5’ - 3’) 1 1.1 SEQ ID NO: 1 TGCAGAGATGATGTAGACAC 2 2.1 SEQ ID NO: 2 AAACAATGTATAAAGCACTT 3 3.1 SEQ ID NO: 3 AGCGCCAAAAATCAGTATTT 4 4.1 SEQ ID NO: 4 CACACGCACGACGACCACTG 4.2 SEQ ID NO: 5 TTTTCAGCAAGGGAAAATTG 5 5.1 SEQ ID NO: 6 AGGGAAACCAGTATTCACGC 5.2 SEQ ID NO: 7 CGTTGCGTATTTTCAAAAAG 6 6.1 SEQ ID NO: 8 ATCAGAGAAAGCATTGCGTG 6.2 SEQ ID NO: 9 TTACTAACAACTCATCAGAG 7 7.1 SEQ ID NO: 10 AATCGTTGCTGCATTGCCAA 8 8.1 SEQ ID NO: 11 GTTCTCATTCTCCATCCTGG 8.2 SEQ ID NO: 12 CTTTCCCTGAAACACCATCC 9 9.1 SEQ ID NO: 13 TCATCAACAGCGTATAGAGG 9.2 SEQ ID NO: 14 TTTGAACATGAGGTGTTACG 10 10.1 SEQ ID NO: 15 CTGGAATATACAAAAACATG 10.2 SEQ ID NO: 16 AAAGGAAACGAAGAAGTTGA 11 11.1 SEQ ID NO: 17 AGCCCACCAAATAAATCAAG 11.2 SEQ ID NO: 18 ACCGTAACGCTGTTATTGCT 12 12.1 SEQ ID NO: 19 GGTGCCAGAGTTACCGCGCA 12.2 SEQ ID NO: 20 TGGCGATAATGCAGTGACCC 13 13.1 SEQ ID NO:21 CCGTCGATTGACACTAAGGG 13.2 SEQ ID NO: 22 CCTGGTGTTCTTAGTAAGCC 14 14.1 SEQ ID NO: 23 TTTAATTCAGGGATAATGTG 14.2 SEQ ID NO: 24 ATCAACGACTGCATGCTGAG 15 15.1 SEQ ID NO: 25 AAAGAGAAGTCAATCCCCAA 15.2 SEQ ID NO: 26 GTTCAGGCAGATACTTAAAC
[0055]
[0056] 16 16.1 SEQ ID NO: 27 CTTATCTCCGGCACTCTCAG 16.2 SEQ ID NO: 28 AAGCATAGACCCTGATGTGT 17 17.1 SEQ ID NO: 29 TGATGTAACTGGGACTGGTG 17.2 SEQ ID NO: 30 TCATCACAATATGCTTCGAC 18 18.1 SEQ ID NO: 31 TATAACACATTACTAATTCG 18.2 SEQ ID NO: 32 GCCCTAATAAAATTAGGGAT 19 19.1 SEQ ID NO: 33 GCTTTCGTAACCGACAGCAT 19.2 SEQ ID NO: 34 GCTCTAAACAGATAAGTGCA 20 20.1 SEQ ID NO:35 AGTATTGCACTATCTCCTGG 20.2 SEQ ID NO: 36 TTTTATGGGGAGATTATCGT 21 21.1 SEQ ID NO: 37 TGTTGAAAGGGAAAATTCTG 21.2 SEQ ID NO:38 AAATGAACCCTGGCTGAAGG
[0057]
[0058] In one embodiment, a guide RNA (gRNA) for genetic modification of host microorganism according to this invention has nucleotide sequence (5’ - 3’) selected from any one or more of nucleotide sequence number 1 - 38 (SEQ ID NO: 1-38) as shown in Table 1.
[0059] Preferably, the guide RNA for genetic modification of host microorganism according to this invention, wherein a suitable host microorganism is Escherichia coli.
[0060] Most preferably, the guide RNA for genetic modification of host microorganism according to this invention, wherein the most suitable Escherichia coli host microorganism is selected from Escherichia coli C, Escherichia coli MYR428, Escherichia coli MYR1674, Escherichia coli C derivatives, Escherichia coli MYR428 derivatives, and Escherichia coli MYR1674 derivatives.
[0061] In one embodiment, the guide RNA for genetic modification of host microorganism according to this invention, wherein the genetic modification uses a CRISPR / Cas system.
[0062] Preferably, the guide RNA for genetic modification of host microorganism according to this invention uses a CRISPR / Cas system, wherein a suitable CRISPR / Cas system is selected from a CRISPR / Cas 9, a CRISPR / Cas 12, a CRISPR / Cas 13, and a CRISPR / dCas 9.
[0063] Most preferably, the guide RNA for genetic modification of host microorganism according to this invention uses a CRISPR / Cas system, wherein the most suitable CRISPR / Cas system is the CRISPR / Cas 9.The genetic materials have been assembled to construct the gRNA plasmid and REDCas-Cm plasmid as shown in figure 1.
[0064] In one embodiment, the guide RNA for genetic modification of host microorganism according to this invention, wherein the genetic modification is selected from substitution, insertion, addition, deletion, detection, interference, and repression.
[0065] In one embodiment, a CRISPR / Cas system for genetic modification of host microorganism comprising:
[0066] (i) a gRNA plasmid comprising the a guide RNA (gRNA) that is specific to a designed intergenic region.
[0067] There are a promoter and a terminator that are specific to the gRNA, an origin of DNA replication, and an antibiotic selection maker gene located in the plasmid ring.
[0068] The gRNA plasmid further comprises the promoter and terminator specific to the gRNA, the origin of DNA replication, and an antibiotic selection maker gene wherein the gRNA is located between the promoter and the terminator wherein the origin of DNA replication and the antibiotic selection maker gene are located at the remaining other locations.
[0069] Figure la shows one aspect of the gRNA plasmid having promoter at the location in front of the gene or gRNA and the terminator located after gene or gRNA, wherein the selection marker gene using ampicillin antibiotic located in front of the origin of DNA replication which is the region that is not specifically related to the promoter, gRNA, and terminator. Promoter is the short nucleotide sequence located in front of gene or gRNA. The RNA polymerase and protein that is important for DNA decoding such as transcription factor recognizes the nucleotide sequence of this promoter and perform the DNA transcription. The terminator is the short nucleotide sequence located after gene or gRNA. The DNA transcription terminates at this location. For other components in the plasmid vector such as the origin of DNA replication which is the nucleotide sequence that is important for DNA replication which increasing this plasmid vector for further use. The selection marker gene using antibiotic enables the selection of desired plasmid vector because the microorganism having the plasmid vector can grow under the specific antibiotic.
[0070] (ii) a REDCas-Cm plasmid
[0071] This plasmid comprises a first gene cassette comprising a gene encoding the expression of a Cas enzyme which is endonuclease specific to the nucleotide sequence of the gRNA; asecond gene cassete for a Lambda-red comprising gene encoding the expression of the Lambda-red system comprising gam, beta, and exo proteins that enable the DNA recombination process; a promoter and a terminator controlling the expression of the cas gene, gam gene, beta gene, and exo gene; a origin of DNA replication and an antibiotic selection maker gene..
[0072] wherein the promoter is located in front of the first gene cassette and in front of the second gene cassete, with the terminator located behind the respective gene cassete; and wherein the origin of DNA replication and the antibiotic selection marker gene are located at the remaining other locations.
[0073] Figure lb shows one aspect of the REDCas-Cm plasmid component having the promoter at the location in front of cas and another promoter located in front of gam, beta, and exo. The terminator is located after cas, gam, beta, and exo and the origin of DNA replication and the selection marker gene using chloramphenicol antibiotic can be located at the location after cas or any other location that is not related to the promoter, cas, gam, beta, and exo, and the terminater.
[0074] The process starts from the design of the gRNA having size about 17 to 20 base pairs. The terminal of this gRNA has the cuting location of the specific cuting enzyme BbsI on both sides. Then, the plasmid to be used for inserting gRNA is designed to have one more location of the specific cuting enzyme BbsI as well. Then, this gRNA is assembled into the plasmid ring to obtain the gRNA plasmid as shown in figure la. Next is the construction of the REDCas-Cm plasmid which modified to have gene resistant to chloramphenicol antibiotic (CmR) for the ease of selection which is not replicate to the gRNA plasmid having gene resistant to ampicillin antibiotic (AmpR) as shown in figure lb.
[0075] (iii) a repair template
[0076] The repair template comprises nucleotide sequences of the target gene wherein the repair template has a nucleotide sequence size in the range of 100 - 10,000 base pairs and wherein the repair template comprises a target gene selected from genes causing the expression of fluorescent proteins, genes causing genetic transcription, and genes causing the expression of proteins or enzymes related to the synthesis of products.
[0077] The repair template is the nucleotide sequence of the target gene to be inserted or substituted on the genome to be removed by inserted gene. The design of the repair template is shown in figure 2 and 3.Preferably, the CRISPR / Cas system for genetic modification of host microorganism according to this invention, wherein a suitable host microorganism is Escherichia coli.
[0078] Most preferably, the CRISPR / Cas system for genetic modification of host microorganism according to this invention, wherein the most suitable Escherichia coli host microorganism is selected from Escherichia coli C, Escherichia coli MYR428, Escherichia coli MYR1674, Escherichia coli C derivatives, Escherichia coli MYR428 derivatives, and Escherichia coli MYR1674 derivatives.
[0079] The genetic modification method has further details as the following.
[0080] The step of preparing the host microorganism for genetic transfer may be performed by incubating the host microorganism in the suitable medium under sterile condition at the temperature of 30 - 37 °C and shaking at 200 - 350 rpm for 1 - 4 hours. Once the suspension has turbidity measured by the optical density of 0.2 - 0.6 at the wavelength of 600 nm, the suspension is separated by centrifugation at 4,000 - 6,000 rpm for 5 - 10 minutes at the temperature of 4 °C. The cell pellet is collected and mixed with the sterile solution at the temperature of 4 °C. Said solution contains 80 mM magnesium chloride and 20 mM calcium chloride in purified water. The suspension is separated and the cell pellet is dissolved 1 - 3 times. Then, the cell pellet is dissolved with the solution containing 10 - 15 % by volume of glycerol and 0.5 molar calcium chloride in purified water under sterile condition. Then, said suspension is collected under frozen condition at the temperature of -80 °C for the work in the next step.
[0081] Next step is the step for introducing the target gene or transferring the genetic material into the intergenic region of the host microorganism to repair the original genetic material of the host microorganism using CRISPR / Cas system according to this invention (details as described above).
[0082] This step of introducing the target gene is performed by mixing the host microorganism in the solution with the REDCas-Cm plasmid and incubating at the temperature of 4 °C for 10 -30 minutes, incubating at the temperature of 42 °C for 40 - 90 seconds, and incubating at the temperature of 4 °C for 15 - 60 seconds. The introducing of plasmid into microorganism cells can be performed by other method such as electroporation. Then, the suitable culturing medium is added under sterile condition and incubated at the temperature of 30 - 37 °C. Then, the host microorganism is selected that containing the REDCas-Cm plasmid on solid culturing mediumhaving mixture of chloramphenicol antibiotic at the concentration of 25 pg / mL. The microorganism is transferred into liquid culturing medium and incubated at the temperature of 30 - 37 °C and shaken at 200 - 350 rpm. Once the suspension has turbidity measured by the optical density of 0.2 - 0.6 at the wavelength of 600 nm, the suspension is mixed with 0.1 - 1 mM isopropyl -d-l -thiogalactopyranoside solution and continuously incubated at 200 - 350 rpm for 60 minutes. Then, the suspension is separated by centrifugation at 4,000 - 6,000 rpm for 5 - 10 minutes at the temperature of 4 °C. The cell pellet is collected and mixed with sterile purified water at the temperature of 4 °C. The suspension is separated and the cell pellet is dissolved with said solution for 1 - 3 times. Then, the cell pellet is dissolved with the solution containing 10 -15 % by volume of glycerol.
[0083] Then, the host microorganism in glycerol solution is mixed with gRNA plasmid and the repair template in the suitable concentration ratio. Then, said genetic materials and nucleotide are transferred into the host microorganism using electroporation under suitable conditions. The microorganism is selected on the culturing medium containing chloramphenicol antibiotic at the concentration of 25 pg / mL and ampicillin antibiotic at the concentration of 50 pg / mL.
[0084] The step of removing the gRNA plasmid and REDCas-Cm plasmid from the host microorganism after genetic modification of the host microorganism is performed by incubating the modified microorganism in liquid culturing medium at the temperature of 30 - 37 °C and shaken at 200 - 350 rpm for 6 - 16 hours. Said culturing medium contains 2 mg / mL of L-arabinose and 25 pg / mL of chloramphenicol antibiotic. Then, the microorganism that cannot grow in ampicillin antibiotic is selected and incubated in liquid culturing medium at the temperature of 37 - 42 °C and shaken at 200 - 350 rpm for 6 - 16 hours.
[0085] Figure 2 shows one aspect of the insertion step of genetic modification.
[0086] The design of the repair template starts from increasing the genetic materials from upstream location and downstream location of host microorganism that needed to be repaired by polymerase chain reaction. Then, more of less nucleotide or DNA is assembled.
[0087] Figure 3 shows one aspect of the substitution step of genetic modification by removing DNA A and replacing DNA B.
[0088] The following examples aims to describe for better understanding but not for limiting the embodiments. Persons skilled in the art can improve or modify them within the scope described in the claims.Example 1 shows the effectiveness of gene insertion that produce red fluorescent protein into the genetic of the host microorganism according to this invention.
[0089] The effectiveness of the genetic modification of E. coli MYR1674 host microorganism using gene capable of producing red fluorescent protein as the indicator of complete modified microorganism. Table 1 shows the nucleotide sequence of gRNA specific to the nucleotide sequence of the host microorganism for constructing the gRNA plasmid. From table 2, it is found that different designs of gRNA even the same nucleotide region of the host microorganism and using the same repair template, gives different effectiveness of the modification method according to the invention by randomly tested of the microorganism by polymerase chain reaction. The highest reaction may be 100 %. However, the effectiveness of the genetic modification of the host microorganism has no relationship to the gene expression that has been inserted into the genome of the microorganism because the effectiveness of the genetic modification is only the test for genetic modification method. Therefore, the gene expression has been tested as shown in the following example 2 and 3.
[0090] Table 2: The number of tested microorganisms for the effectiveness of the genetic modification of the host microorganism according to this invention
[0091] No. of gRNA Numbers of modified Effectiveness of the colony / numbers of randomly modification (%)
[0092] tested colony
[0093] 1.1 5 / 8 62.5
[0094] 2.1 8 / 10 80
[0095] 3.1 1 / 8 12.5
[0096] 4.1 0 / 8 0
[0097] 4.2 1 / 8 12.5
[0098] 5.1 7 / 8 87.5
[0099] 5.2 0 / 8 0
[0100] 6.1 2 / 8 25
[0101] 6.2 0 / 8 0
[0102] 7.1 1 / 8 12.5
[0103] 8.1 8 / 8 100
[0104]
[0105] 8.2 4 / 8 50
[0106] 9.1 2 / 8 25
[0107] 9.2 3 / 8 37.5
[0108] 10.1 5 / 8 62.5
[0109] 10.2 7 / 8 87.5
[0110] 11.1 8 / 8 100
[0111] 11.2 0 / 8 0
[0112] 12.1 2 / 8 25
[0113] 12.2 0 0
[0114] 13.1 2 / 8 25
[0115] 13.2 2 / 8 25
[0116] 14.1 6 / 8 75
[0117] 14.2 5 / 8 62.5
[0118] 15.1 8 / 8 100
[0119] 15.2 1 / 8 12.5
[0120] 16.1 5 / 8 62.5
[0121] 16.2 2 / 8 25
[0122] 17.1 8 / 8 100
[0123] 17.2 8 / 8 100
[0124] 18.1 8 / 8 100
[0125] 18.2 0 / 8 0
[0126] 19.1 7 / 8 87.5
[0127] 19.2 7 / 8 87.5
[0128] 20.1 8 / 8 100
[0129] 20.2 5 / 8 62.5
[0130] 21.1 8 / 8 100
[0131] 21.2 6 / 8 75
[0132]
[0133] Example 2 shows ability of the gene expression that produces red fluorescent protein in the genetic of the host microorganism according to this invention.After selecting E. coli MYR1674 derivatives host microorganism according to this invention as shown in example 1 having red fluorescent protein gene in different genome locations such as location 1 (gRNA 1.1), location 2 (gRNA 2.1), location 3 (gRNA 3.1), location 4 (gRNA 4.2), location 5 (gRNA 5.1), location 6 (gRNA 6.1), location 7 (gRNA 7.1) location 8 (gRNA 8.1), location 9 (gRNA 9.2), location 10 (gRNA 10.2) location 11 (gRNA 11.1), location 12 (gRNA 12.1), location 13 (gRNA 13.1), location 14 (gRNA 14.1), location 15 (gRNA 15.1), location 16 (gRNA 16.1), location 17 (gRNA 17.1), location 18 (gRNA 18.1), location 19 (gRNA 19.2), location 20 (gRNA 20.1), and location 21 (gRNA 21.1). The microorganism is incubated in the liquid culturing medium (LB) under the same incubation conditions, the fluorescence light excited at 586 nm and the emission of 613 nm. The controls are the control set 1 to the control set 3 which are M9 minimal medium, host microorganism control, and the host microorganism modified with rfp plasmid respectively.
[0134] The result of the comparison of the luminescence of the microorganism is shown in figure 4. It is found that the host microorganisms modified with different gRNA give close red luminescence which are higher than the original host microorganism having no modification and giving lower red luminescence than the microorganism modified with rfp plasmid. This confirms that the host microorganism has been modified and successfully contains the gene that producing luminescent protein.
[0135] Example 3 shows the ability of T7 RNA polymerase gene expression in the modified microorganism by gene insertion according to this invention.
[0136] The T7 RNA polymerase gene is the gene acquired from E. coli BL21 (DE3). Once gene expresses T7 RNA polymerase, the DNA transcription of the microorganism occurs in the gene transcription step. The T7 RNA polymerase is specific to the gene having T7 promoter for the transcription. This promoter is commonly used in the studies and industrials because it can be suitably controlled in gene expression under this T7 promoter such as the use of lactose or isopropyl -d- 1 -thiogalactopyranoside.
[0137] In this example, the E. coli MYR428 and E. coli MYR1674 host microorganism in which the E. coli MYR1674 is modified from the E. coli MYR428. This can be said that the E. coli MYR1674 is the E. coli MYR428 derivatives. Both microorganism strains have been inserted with T7 RNA polymerase gene having 2766 base pairs in location NCI (gRNA 1.1) by the method according to this invention. The effectiveness of the modification is 100 % in E. coliMYR428 and 75 % in E. coli MYR1674. When inserting the plasmid containing T7 promoter into the E. coli MYR428 derivatives and the E. coli MYR1674 derivatives having 7'7 RNA polymerase gene, the expression of the enzyme in that plasmid is found as shown in figure 5 which is the test of the effectiveness of the expression of 7'7 RNA polymerase enzyme using pETDuet-1 plasmid as the control set and pETDuet-1 - / wxCD7L4B plasmid as the testing set that expresses the gene expression and luciferase giving the luminescence light when gene is induced by T7 promoter.
[0138] When culturing the E. coli MYR428 derivatives and the E. coli MYR1674 derivatives containing T7 RNA polymerase gene and having pETDuet-1 plasmid as the control set and pETDuet-1 -luxCDEAB plasmid as the testing set in the liquid culturing medium LB and shaken in the incubator at the temperature of 37 °C for 3 - 4 hours. The T7 RNA polymerase gene is induced with IPTG at the concentration of 0.5 mM and shaken in the incubator at the temperature of 25 °C for 2, 4, and 6 hours to measure the luminescence intensity using the fatty acids obtained from the microorganism as the precursor for the luminescence light.
[0139] From the result shown in figure 5, it is found that both E. coli MYR428 derivatives and E. coli MYR1674 derivatives having 7'7 RNA polymerase gene insertion and containing pETDuet-1 -luxCDEAB plasmid show the light intensity at 2, 4, and 6 hours whereas the pETDuet-1 plasmid control shows no gene expression. Therefore, the E. coli MYR428 derivatives and the E. coli MYR1674 derivatives can be modified and provide the 7'7 RNA polymerase gene expression by giving luminescence light once having gene expression and luciferase. However, it is found that the E. coli MYR428 derivatives that is inserted with 7'7 RNA polymerase gene and having pETDuet-1 -luxCDEAB plasmid gives lower luminescence intensity than the E. coli MYR1674 derivatives that is inserted with 7'7 RNA polymerase gene and having pETDuet-1 -luxCDEAB plasmid because the genome of the E. coli MYR1674 derivatives has been modified and causes the accumulation of acetyl-CoA, an intermediate that causes more fatty acid and may cause the luciferase system to have an increased precursor. This leads to increased luminescence light.
[0140] BEST MODE OR PREFERRED EMBODIMENT OF THE INVENTION
[0141] Best mode or preferred embodiment of the invention is as provided in the description of the invention.
Claims
Claims1. A guide RNA (gRNA) for genetic modification of host microorganism, wherein the guide RNA has nucleotide sequence (5’ - 3’) selected from any one or more of nucleotide sequence number 1 -38 (SEQ ID NO: 1-38).
2. The guide RNA for genetic modification of host microorganism according to claim 1 , wherein a suitable host microorganism is Escherichia coli.
3. The guide RNA for genetic modification of host microorganism according to claim 2, wherein the most suitable Escherichia coli host microorganism is selected from Escherichia coli C, Escherichia coli MYR428, Escherichia coli MYR1674, Escherichia coli C derivatives, Escherichia coli MYR428 derivatives, and Escherichia coli MYR1674 derivatives.
4. The guide RNA for genetic modification of host microorganism according to claim 1 , wherein the genetic modification uses a CRISPR / Cas system.
5. The guide RNA for genetic modification of host microorganism according to claim 4, wherein a suitable CRISPR / Cas system is selected from a CRISPR / Cas 9, a CRISPR / Cas 12, a CRISPR / Cas 13, and a CRISPR / dCas 9.
6. The guide RNA for genetic modification of host microorganism according to claim 5, wherein the most suitable CRISPR / Cas system is the CRISPR / Cas 9.
7. The guide RNA for genetic modification of host microorganism according to claim 1 , wherein the genetic modification is selected from substitution, insertion, addition, deletion, detection, interference, and repression.
8. A CRISPR / Cas system for genetic modification of host microorganism comprising:(i) a gRNA plasmid comprising the gRNA according to claim 1 that is specific to a designed intergenic region;(ii) a REDCas-Cm plasmid; and(iii) a repair template comprising a nucleotide sequence of a target gene.
9. The CRISPR / Cas system for genetic modification of host microorganism according to claim 8, wherein a suitable host microorganism is Escherichia coli.
10. The CRISPR / Cas system for genetic modification of host microorganism according to claim 9, wherein the most suitable Escherichia coli host microorganism is selected from Escherichia coli C, Escherichia coli MYR428, Escherichia coli MYR1674, Escherichia coli C derivatives, Escherichia coli MYR428 derivatives, and Escherichia coli MYR1674 derivatives.
11. The CRISPR / Cas system for genetic modification of host microorganism according to claim 8, wherein the gRNA plasmid further comprising:a. a promoter and a terminator specific to the gRNA;b. an origin of DNA replication; andc. an antibiotic selection maker gene wherein the gRNA is located between the promoter and the terminator wherein the origin of DNA replication and the antibiotic selection maker gene are located at the remaining other locations.
12. The CRISPR / Cas system for genetic modification of host microorganism according to claim 8, wherein the REDCas-Cm plasmid comprising:a. a first gene cassette comprising a gene encoding the expression of a Cas enzyme specific to the nucleotide sequence of the gRNA;b. a second gene cassette for a Lambda-red comprising gene encoding the expression of the Lambda-red system comprising gam, beta, and exo proteins;c. a promoter and a terminator controlling the expression of the cas gene, gam gene, beta gene, and exo gene;d. a origin of DNA replication; ande. an antibiotic selection maker gene;wherein the promoter is located in front of the first gene cassette and in front of the second gene cassette, with the terminator located behind the respective gene cassette; andwherein the origin of DNA replication and the antibiotic selection marker gene are located at the remaining other locations.
13. The CRISPR / Cas system for genetic modification of host microorganism according to claim 8, wherein the repair template has a nucleotide sequence size in the range of 100 - 10,000 base pairs.
14. The CRISPR / Cas system for genetic modification of host microorganism according to claim 8, wherein the repair template comprises a target gene selected from genes causing the expression of fluorescent proteins, genes causing genetic transcription, and genes causing the expression of proteins or enzymes related to the synthesis of products.
15. A genetic modification method of host microorganism for target gene expression comprising the following steps:a. introducing the target gene into a designated intergenic region of the host microorganism using the CRISPR / Cas system according to claim 8; andb. removing of the gRNA plasmid and the REDCas-Cm plasmid from the genetically modified microorganism.
16. The genetic modification method of host microorganism for target gene expression according to claim 15, wherein a suitable host microorganism is Escherichia coli.
17. The genetic modification method of host microorganism for target gene expression according to claim 16, wherein the most suitable Escherichia coli host microorganism is selected from Escherichia coli C, Escherichia coli MYR428, Escherichia coli MYR1674, Escherichia coli C derivatives, Escherichia coli MYR428 derivatives, and Escherichia coli MYR1674 derivatives.
